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Background
Melanoma is one of the most aggressive and chemoresist-
ant cancer types in humans. Especially in late stages, effec-
tive therapeutic approaches are not available. Statins have
been investigated for their anti-proliferative and pro-
apoptotic effects in many tumor cells including
melanoma [1]. Beside paracrine signalling, melanoma
cells rely on a wide range of autocrine cytokine loops.
Methods and results
We have therefore screened the serum-free supernatant of
simvastatin-treated 518A2 melanoma cells for cytokines.
While INF-γ, TNF-α, IL-1α, IL-1β, IL-10 and IL-12 were
not regulated by simvastatin, most strikingly, IL-6 levels
were significantly decreased. IL-6 is an important prog-
nostic marker in late stage melanoma. Due to this crucial
role in the autocrine regulation of the tumour growth this
cytokine was investigated in greater detail. A375 and
518A2 melanoma cells were transfected with a fluorescent
Stat-3 fusion protein and showed IL-6-mediated translo-
cation of Stat-3-YFP into the nucleus. This was followed
by a transient phosphorylation of Stat-3. Conversely, the
''IL-6-insensitive'' melanoma cell lines, WM278 and
WM793B, showed constitutively active Stat-3 phosphor-
ylation and virtually no regulation upon IL-6 addition.
Interestingly, the latter cells were approximately 10-fold
less susceptible toward statin-induced caspase 3 activation
compared to A375 and 518A2 melanoma cells. Moreover,
addition of IL-6 to simvastatin-treated A375 and 518A2
melanoma cells abrogated the pro-apoptotic effect of stat-
ins.
Conclusion
Taken together, theses data may open a possible new ther-
apeutic window for statins in late-stage melanoma ther-
apy which is based on IL-6 suppression by simvastatin in
the metastatic melanoma cell lines A375 and 518A2,
while early-stage melanoma cell lines, WM278 and
WM793B were virtually insensitive to statin treatment.
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